Associated tags: Finance, Professional Services, Sarissa, Security (finance), Wall Street, Professional corporation, Health, BLUE, Glenview Capital Management, Annual general meeting, Mass meeting, Amarin, Auction, Cardiology, Pharmaceutical, BUT, MAKE, Internet, Banking, ALKS
Locations: UNITED STATES, NORTH AMERICA, CONNECTICUT, NETHERLANDS, SPAIN, EUROPE, SCOTLAND, CHINA
Retrieved on:
Thursday, December 21, 2023
Biotechnology,
Mental Health,
Health,
Pharmaceutical,
Clinical Trials,
Sun Pharma,
LYNX,
Reuters,
Risperidone,
MIT,
Polaris Partners,
Engineering,
Pharmaceutical industry Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced the closing of a $101 million Series E financing round.
Key Points:
- Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced the closing of a $101 million Series E financing round.
- Lyndra’s investigational therapies are enabled by the company’s LYNX® drug delivery platform, which creates long-acting oral medicines that can be taken once weekly.
- The platform originated from the Bob Langer and Gio Traverso Laboratories at MIT, with which Lyndra has an exclusive technology license.
- The round follows a $20.3 million Series D financing led by Polaris Partners that was completed in June 2023.
Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
Key Points:
- Sarissa Capital Management LP (“Sarissa”) today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):
Sarissa believes Amarin’s stock is significantly undervalued.
- We hope that recent progress detailed below will cause the stock to begin to reflect the value we think it has.
- We have never sold any shares of Amarin and have only increased our position since we made the investment.
- We are pleased with the progress that Amarin has made to date and expect the value to be reflected in the stock price over time.
Finance,
Business,
Banking,
Professional Services,
Other Professional Services,
BLUE,
Shareholder,
Internet,
Glenview Capital Management,
Telephone,
Annual,
Annual Meetings of the International Monetary Fund and the World Bank Group,
Wall Street,
ALKS,
Sequah Medicine Company,
ARIAD Pharmaceuticals,
ISS,
Alkermes (company),
Management,
Security (finance),
Alkermes,
Sarissa Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.
Key Points:
- Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.
- If shareholders are not added to the board, we fear that Pops will continue to run the company as he pleases and never address its fundamental issues.
- The board steadfastly refuses to add our nominees, including Sarah Schlesinger, who the Nom-Gov committee at Alkermes previously acknowledged would be a qualified board candidate and who ISS recommended that shareholders vote “FOR”.
- Shareholders face an important decision at the upcoming Alkermes annual shareholder meeting.
Other Professional Services,
Professional Services,
Business,
Finance,
BLUE,
Shareholder,
Glenview Capital Management,
Internet,
Telephone,
Annual,
NUALS Arts and Literary Annual Meet,
Wall Street,
ALKS,
Sarissa,
Security (finance),
Auction,
Alkermes We urge all shareholders to vote "FOR" the election of the Sarissa Nominees, “AGAINST” the compensation of the Company’s named executive officers, and "FOR" all other proposals in our proxy statement.
Key Points:
- We urge all shareholders to vote "FOR" the election of the Sarissa Nominees, “AGAINST” the compensation of the Company’s named executive officers, and "FOR" all other proposals in our proxy statement.
- Shareholders are advised to read the definitive proxy statement and other documents related to the Annual Meeting as they contain important information.
- The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
- The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.
Banking,
Professional Services,
Finance,
BLUE,
Shareholder,
Face,
Internet,
Glenview Capital Management,
Telephone,
Annual,
Annual Meetings of the International Monetary Fund and the World Bank Group,
Wall Street,
Janssen,
History,
ALKS,
Risk,
Sarissa,
ISS,
Alkermes (company),
Audit,
Management,
Security (finance),
Alkermes Shareholders should ask themselves a simple question – why would a purportedly well-functioning company undertake such actions?
Key Points:
- Shareholders should ask themselves a simple question – why would a purportedly well-functioning company undertake such actions?
- Like ISS, we believe it is important to add direct shareholder representation to the Alkermes board.
- The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
- The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.
Banking,
Professional Services,
Finance,
BLUE,
Shareholder,
Failure,
Internet,
Glenview Capital Management,
Telephone,
Annual,
Annual Meetings of the International Monetary Fund and the World Bank Group,
Wall Street,
ALKS,
Sarissa,
ISS,
Alkermes (company),
Management,
Security (finance),
Auction,
Alkermes Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):
Key Points:
- Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS):
We are pleased that ISS recognizes the compelling case for change to the Alkermes board.
- ISS also concludes that with the pending spin of its cancer business, the value of Alkermes’ incumbent director Richard Gaynor will be reduced and therefore he should be removed from the Alkermes board.
- Fellow Alkermes shareholders face an important decision at our upcoming annual shareholder meeting.
- Like ISS, we believe it is important to add direct shareholder representation to the Alkermes board.
Professional Services,
Finance,
BLUE,
Shareholder,
Glenview Capital Management,
Internet,
Telephone,
Annual,
NUALS Arts and Literary Annual Meet,
Wall Street,
ALKS,
Sarissa,
Security (finance),
Auction,
Alkermes Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:
Key Points:
- Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) accessible at the link below:
If you have any questions regarding your BLUE universal proxy card or need assistance in executing your proxy card, please contact:
Your vote at Alkermes' Annual General Meeting of Shareholders on June 29, 2023 is very important.
- If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.
- The definitive proxy statement and other relevant documents are available at no charge on the SEC’s website at www.sec.gov .
- The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge at www.upgradealkermes.com or by directing a request to Sarissa Capital’s proxy solicitor, D.F.
Finance,
Oncology,
General Health,
Health,
Mental Health,
Banking,
Professional Services,
Other Health,
Pressure,
BLUE,
Shareholder,
Internet,
Biogen,
Telephone,
Annual,
Clinical trial,
Annual Meetings of the International Monetary Fund and the World Bank Group,
Cancer,
Wall Street,
Sale,
ALKS,
NBI,
Sarissa,
Capital,
Nature Biotechnology,
Research,
Fraud,
Letter,
Psychiatry,
Alkermes (company),
Management,
Security (finance),
Alkermes Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
Key Points:
- Sarissa Capital today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS):
We are one of Alkermes’ largest, long-term shareholders, owning nearly $450 million of stock.
- We believe Pops understands that shareholder representation on the board will likely result in greater accountability and oversight.
- Moreover, they each understand that they work for the shareholders and will provide essential oversight of management and accountability to shareholders.
- We urge our fellow Alkermes shareholders to vote the BLUE universal proxy card “FOR” all Sarissa Nominees to provide much needed oversight and accountability at Alkermes.
Banking,
Professional Services,
Finance,
BLUE,
Shareholder,
Glenview Capital Management,
Internet,
Telephone,
Annual,
NUALS Arts and Literary Annual Meet,
Wall Street,
ALKS,
Security (finance) If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.
Key Points:
- If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.
- Shareholders are advised to read the definitive proxy statement and other documents related to the Annual Meeting as they contain important information.
- The definitive proxy statement and other relevant documents filed by Sarissa Capital are available at no charge on the SEC’s website at www.sec.gov and at www.upgradealkermes.com .
- The definitive proxy statement and other relevant documents filed by Sarissa Capital are also available at no charge by directing a request to Sarissa Capital’s proxy solicitor, D.F.
Professional Services,
Health,
Finance,
General Health,
Pharmaceutical,
Banking,
Biotechnology,
BLUE,
Shareholder,
Internet,
Telephone,
Annual,
Annual Meetings of the International Monetary Fund and the World Bank Group,
Cancer,
Wall Street,
Elliott Investment Management,
ALKS,
EBITDA,
Traction,
IBB,
NBI,
Capital,
Nature Biotechnology,
Research,
Letter,
Psychiatry,
Alkermes (company),
Management,
Cryptocurrency,
Security (finance),
Biogen,
Alkermes,
Sarissa Richard Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago.
Key Points:
- Richard Pops has presided over tremendous shareholder value destruction since becoming CEO of Alkermes over thirty years ago.
- For too long, Alkermes has been run for the benefit of management and not for shareholders.
- In addition to issues with poor governance, expense management and capital allocation, Alkermes is basically a patchwork of subscale businesses.
- If you vote by internet or telephone, you will be required to provide the unique control number printed on your BLUE universal proxy card.
